( mycin 91.5% (205/224)compared to Biaxi...)Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial,Health

mycin 91.5% (205/224) compared to Biaxin(R) 95.9% (212/221) [-9.1, +0.3] p=0.0775). Based on the 95.9% clinical cure rate for Biaxin(R) being 90% or greater, a delta value of 10% or less on the lower bound and greater than zero on the upper bound [-9.1, +0.3] establishes non-inferiority. Under this analysis, the Company met the non-inferiority endpoint of per protocol clinical cure rate. Since p>0.05, there is not a statistically significant difference between cethromycin and Biaxin(R), which supports non-inferiority.

Supplemental Data

The Company today confirmed supplemental efficacy data with its clinical research organization and announced results in the following endpoints:

    -- Modified intent-to-treat clinical cure rate -- cethromycin 82.9%

       (213/257) compared to Biaxin(R) 88.5% (224/253) [-11.9, +0.6]

       (p=0.0769).  Based on the 88.5% clinical cure rate for Biaxin(R) being

       between 80% and 90%, a delta value of 15% or less on the lower bound

       and greater than zero on the upper bound [-11.9, +0.6] establishes

       non-inferiority.  Under this analysis, the study met the endpoint of

       modified intent-to-treat clinical cure rate.  Since p>0.05, there is

       not a statistically significant difference between cethromycin and

       Biaxin(R), which supports non-inferiority.

    -- Per protocol radiographic success rate -- cethromycin 94.2% (211/224)

       compared to Biaxin(R) 95.9% (212/221) [-6.0, +2.5] (p=0.5130).  Based

       on the 95.9% clinical cure rate for Biaxin(R) being 90% or greater, a

       delta value of 10% or less on the lower bound and greater than zero on

       the upper bound [-6.0, +2.5] establishes non-inferiority.  Under this

       analysis, the study met the endpoint of per protocol radiographic

       success rate.  Since p>0.05, there is not a statistically significant

       difference between cethromycin and Biaxin(R), which supports non-

       inferiority
'"/>




Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From
Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month
Clinical-Extension Study of Subcutaneous Methylnaltrexone for the
Treatment of Opioid-Induced Constipation in Patients with Advanced
Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell
Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study
Demonstrating Safety and Statistically Significant Improvement in
Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary
Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and
Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere
(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate
Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced
Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma